{"id":"W2996686534","doi":"10.1016/j.jval.2019.09.284","title":"PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Dabrafenib; Medicine; Trametinib; Oncology; Internal medicine; Cohort; Placebo; Adverse effect; Adjuvant; Melanoma; Surgery; Metastatic melanoma; Cancer; Pathology; Vemurafenib; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003294927,0.0009107575,0.001976173,0.001579838,0.0005386049,0.002172648,0.001242405,0.0006792953,0.003300947],"category_scores_gemma":[0.007413842,0.00050705,0.003612198,0.002651251,0.0007184832,0.0005796144,0.0008453827,0.001543135,0.0001702093],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.04421088,"about_ca_system_score_gemma":0.04932344,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9217287,"about_ca_topic_score_gemma":0.9233469,"domain_scores_codex":[0.9975467,0.0008627354,0.0000961181,0.00013386,0.000602912,0.0007576818],"domain_scores_gemma":[0.9970554,0.001232759,0.0002914691,0.00007979904,0.0008676353,0.0004729603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.03101422,0.001210125,0.1589149,0.002882374,0.0158155,0.001153901,0.0002835827,0.6271828,0.002160545,0.01876044,0.02178765,0.1188339],"study_design_scores_gemma":[0.007595779,0.004965648,0.4223297,0.001521689,0.02508982,0.0008012094,0.001956566,0.4981557,0.002198853,0.01079354,0.02427053,0.0003209176],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9431768,0.01472889,0.00216931,0.005651911,0.0001136378,0.0006215371,0.01775156,0.00007435215,0.01571198],"genre_scores_gemma":[0.9918535,0.002069112,0.0007704216,0.0003348696,0.00003444834,0.00006236378,0.003296146,0.0000133397,0.001565879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07827127,"threshold_uncertainty_score":0.3207739,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1878447953967277,"score_gpt":0.4213764691044462,"score_spread":0.2335316737077185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}